Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Complementary and Alternative Medicine

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Samsoeum water extract attenuates allergic airway inflammation via modulation of Th1/Th2 cytokines and decrease of iNOS expression in asthmatic mice

BMC Complementary and Alternative MedicineThe official journal of the International Society for Complementary Medicine Research (ISCMR)201515:47

https://doi.org/10.1186/s12906-015-0561-3

Received: 19 August 2014

Accepted: 18 February 2015

Published: 10 March 2015

Abstract

Background

Samsoeum has long been used in Korea and other Asian countries as a traditional medicine to treat various diseases. In the present study, we investigated the antiasthma effect of the herbal medicine Samsoeum water extract (SSEW) using an in vivo ovalbumin (OVA)-induced asthmatic model.

Methods

Female BALB/c mice were sensitized by an intraperitoneal injection of OVA and subsequently challenged with nebulized OVA. We investigated the number of inflammatory cells, the production of Th1/Th2 cytokines and chemokine in bronchoalveolar lavage fluid (BALF), histological changes in lung tissue, the infiltration of inflammatory cells and hyperplasia of goblet cells in lung tissue, the levels of immunoglobulin E (IgE) in BALF and plasma, and the expression of inducible nitric oxide synthase (iNOS) in lung tissue.

Results

Our findings indicated that SSEW decreased the accumulation of inflammatory cells (particularly, eosinophil and neutrophil) and regulated the balance in the production of Th1/Th2 cytokines and chemokine in BALF. Moreover, SSEW suppressed the level of IgE in BALF and plasma, and inhibited the infiltration of inflammatory cells, hyperplasia of goblet cells, and the expression of iNOS in lung tissue.

Conclusions

Collectively, these results suggest that, because of its anti-inflammatory and antiasthma properties, SSEW may be useful in reducing airway inflammation in the treatment of allergic asthma.

Keywords

SamsoeumAsthmaInflammatory cellsTh1/Th2 cytokinesiNOS

Background

Allergic asthma is a chronic inflammatory disease of the airway that is characterized by airway inflammation, intense eosinophilia, lymphocyte infiltration, and mucus overproduction [1]. Allergen-specific CD4+ T cells play a pivotal role in the development of asthma [2]. Th1 cells allergies are caused by characteristic immunoresponses to allergens, primarily mediated by Th2 cells. Th2 cells synthesize high levels of interleukin 4 (IL-4), IL-5, and IL-13, which leads to the release of allergen-specific immunoglobulin E (IgE) and the production of mediators from mast cells [3]. It has largely been aceepted that an imbalance between Th1 and Th2 cells leads to the clinical expression of this allergic disease [4]. Spina et al. reported that the pathophysiology of asthma is related to a Th1/Th2 cell imbalance in the airways [5]. Because asthma is associated with decreased Th2 responses, enhanced Th1 responses may suppress the development of allergic airway inflammation.

Lung inflammation in allergic asthma is induced by a cascade of reactions involving several mediators, including nitric oxide (NO). NO plays an essential role in regulating airway function and in the pathophysiology of inflammatory airway diseases. NO is synthesized from L-arginine by NO synthase (NOS), which exists in three isoforms: neuronal NOS (nNOS: NOS-1), endothelial NOS (eNOS: NOS-3), and inducible NOS (iNOS: NOS-2). It is now known that each of these isoforms may be expressed in a variety of tissues and cell types [6]. However, iNOS is induced after exposure to proinflammatory cytokines and is expressed in epithelial and inflammatory cells of the airway [7]. Several studies have suggested that the downregulation of iNOS expression inhibits airway inflammation in an asthmatic model [8,9].

Traditional herbal medicines are composed of various components. These components exhibit various therapeutic effects; thus, mixed herbal medicines are applied to multiple diseases [10]. Samsoeum (known as Shen-su-yin in Chinese) is composed of 12 different crude components obtained from natural herbs. It is one of the major traditional herbal medicines that are used widely in the treatment of headache, fever, cough and rhinorrhea caused by cold wind. According to previous studies, Samsoeum has immunomodulating [11] and antiallergic effects [12]. However, there is little information on the mechanism underlying the antiasthmatic effect of Samsoeum. In particular, the inhibitory mechanism of Samsoeum on airway inflammation remains unclear. Therefore, we examined the protective effects of a Samsoeum water extract (SSEW) on the airway inflammation induced by ovalbumin (OVA) challenge.

Methods

Preparation of the SSEW

A voucher specimen of Samsoeum (2008-KE28) is available at the Herbal Medicine Formulation Research Group, Korea Institute of Oriental Medicine. Samsoeum was prepared in our laboratory from a mixture of chopped crude herbs that were purchased from Omniherb (Korea; Geochang, Jecheon, Geumsan, Yeongcheon, and Jeju) and HMAX (China). Professor Je-Hyun Lee of Dongguk University, Gyeongju, Republic of Korea, confirmed the identity of each crude herb. A decoction of Samsoeum was prepared using a mixture of herbal medicines according to composition in the laboratory (Table 1). The herbal medicines of Samsoeum were extracted in distilled water at 100°C for 2 h. The extract solution was evaporated to dryness and then frozen to a dry powder (yield, 18.6%).
Table 1

Crude components of Samsoeum

Scientific name

Amount (g)

Company of purchase

Source

Perillae Herba

3.75 (9.1%)

Omniherb

Geochang, Korea

Puerariae Radix

3.75 (9.1%)

Omniherb

Jecheon, Korea

Pinelliae Tuber

3.75 (9.1%)

HMAX

China

Anthrisci Radix

3.75 (9.1%)

HMAX

China

Ginseng Radix

3.75 (9.1%)

Omniherb

Geumsan, Korea

Poria Sclerotium

3.75 (9.1%)

Omniherb

Yeongcheon, Korea

Aurantii Fructus

2.8125 (6.8%)

HMAX

China

Platycodonis Radix

2.8125 (6.8%)

Omniherb

Yeongcheon, Korea

Glycyrrhizae Radix

2.8125 (6.8%)

HMAX

China

Citri Unshius Pericarpium

2.8125 (6.8%)

Omniherb

Jeju, Korea

Zingiberis Rhizoma

3.75 (9.1%)

Omniherb

Yeongcheon, Korea

Zizyphi Fructus

3.75 (9.1%)

Omniherb

Yeongcheon, Korea

Total amount

41.25 (100%)

  

Animals

Specific pathogen-free female BALB/c mice (6 weeks of age) were purchased from Orient Co. (Seoul, Korea) and used after 1 week of quarantine and acclimatization. Mice were maintained in an animal facility under standard laboratory conditions for 1 week prior to experiments, and were provided with water and standard chow ad libitum. All experimental procedures were performed in compliance with the NIH guidelines for the Care and Use of Laboratory Animals and were approved by Korea Institute of Oriental Medicine Institutional Animal Care and Use Committee (Approval number: #10-011). The animal handling followed the dictates of the National Animal Welfare Law of Korea.

OVA-induced allergic asthma

The mice were randomly divided into 5 groups (n = 6 per group): NC (normal control group, PBS sensitization/challenge), OVA (OVA sensitization/challenge), Mon (OVA sensitization/challenge + oral gavage of 30 mg/kg of montelukast), SSEW-100 (OVA sensitization/challenge + oral gavage of 100 mg/kg of SSEW), and SSEW-200 (OVA sensitization/challenge + oral gavage of 200 mg/kg of SSEW).

OVA sensitization and airway challenge were performed as described previously [13]. Briefly, mice were sensitized on days 0 and 14 by intraperitoneal injection of 20 μg of OVA emulsified in 2 mg of aluminum hydroxide in 200 μL of PBS buffer (pH 7.4). On days 21, 22, and 23 after the initial sensitization, mice received an airway challenge with OVA (1%, w/v, in PBS) for 1 h using an ultrasonic nebulizer (NE-U12; Omron Corp., Tokyo, Japan). SSEW was dissolved in PBS and was prepared fresh daily before each treatment. SSEW was administered by gavage to mice at doses of 100 mg/kg or 200 mg/kg once daily from days 18 to 23. Normal- and positive-control mice were administered PBS or Mon (30 mg/kg in PBS) orally, respectively. Mon was developed as a cysteinyl leukotriene (cys-LT)-1 receptor antagonist [14] and was introduced into the market after successful clinical evaluation in patients with aspirin-sensitive asthma, nocturnal exacerbation of asthma, and allergic asthma [15].

After the OVA challenge, bronchoalveolar lavage fluid (BALF) samples were obtained from the mice and processed, and inflammatory cells were counted as described previously [13]. Briefly, mice were sacrificed by intraperitoneal injection of pentobarbital (50 mg/kg; Hanlim Pharm. Co., Seoul, Korea) 48 h after the last challenge, and tracheostomy was performed. A schematic diagram of the treatment schedule is shown in Figure 1. To obtain BALF, ice-cold PBS (0.5 mL) was infused into the lung and withdrawn via tracheal cannulation three times (total volume, 1.5 mL). The number of total inflammatory cells was assessed by counting cells in at least five squares of a hemocytometer after exclusion of dead cells by Trypan blue staining. To determine differential cell counts, 100 μL of BALF was centrifuged onto slides using a cytospin machine (Hanil Science Industrial, Seoul, Korea) (200 g, 4°C, 10 min). The slides were dried and the cells were fixed and stained using the Diff-Quik® staining reagent (B4132-1A; IMEB Inc., Deerfield, IL), according to the manufacturer’s instructions. The supernatant obtained from BALF was stored at −70°C for biochemical analysis.
Figure 1

Asthmatic mouse model: airway inflammation and treatment with SSEW.

Measurement of the levels of Th1/Th2 cytokines, chemokines, and IgE

The levels of TNF-α, eotaxin, IL-4, IL-5, IL-10, IL-13, and IL-33 in BALF were measured using enzyme-linked immunosorbent assay (ELISA) kits (BioSource International, Camarillo, CA) according to the manufacturer’s protocols. The detection range of IL-13 is 3.9 pg/mL to 250 pg/mL, and IL-5 is 7.8 pg/mL to 500 pg/mL. The detection ranges of TNF-α and IL-4 are 15.6 pg/mL to 1000 pg/mL, and eotaxin, IL-10 and IL-33 are 31.25 pg/mL to 2000 pg/mL. The levels of total IgE and OVA-Specific in BALF and plasma were measured using ELISA. Microtiter plates were coated with anti-IgE antibodies (anti-mouse IgE; 10 g/mL; Serotec, Oxford, UK) in PBS-Tween 20, and incubated with BALF or plasma. The plates were then washed four times, and 200 μL of O-phenylenediamine dihydrochloride (Sigma-Aldrich, St. Louis, MO) was added to each well. The plates were incubated for 10 min in the dark and the absorbance was then measured at 450 nm.

Lung tissue histopathology

After BALF samples were obtained, lung tissue was fixed in 10% (v/v) neutral-buffered formalin. Tissues were embedded in paraffin, sectioned at a 4 μm thickness, and stained with hematoxylin and eosin stain (H&E) solution (hematoxylin, Sigma MHS-16, and eosin, Sigma HT110-1-32) and periodic acid–Schiff (PAS) (IMEB Inc., San Marcos, CA) to estimate inflammatory cell accumulation and mucus production, respectively. Quantitative analysis for airway inflammation and mucus secretion was evaluated using a MetaMorph Offline version 7.7.0.0 image analysis software (Molecular Devices Inc., Sunnyvale, CA, USA).

Western blotting

Equal amounts of total lung protein (30 μg) were heated at 100°C for 5 min, loaded onto 8% sodium dodecylsulfate polyacrylamide gel electrophoresis gels, and electrophoresed. The proteins were then transferred to a nitrocellulose membrane (at 100 V for 2 h). The membrane was blocked for 1 h with Tris-buffered saline containing 0.05% Tween-20 (TBST) plus 5% skim milk, followed by incubation with anti-iNOS (sc-7271, 1:1000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA) and anti-β-actin (#4967S, 1:1000 dilution; Cell Signaling Technology, Danvers, MA) antibodies overnight at 4°C. The embrane was washed three times with TBST at intervals of 10 min and then incubated with a horseradish peroxidase (HRP)-conjugated secondary antibody (iNOS: anti-mouse, β-actin: anti-rabbit 1:3000 dilution; Jackson ImmunoResearch, West Grove, PA) for 1 h at room temperature. The membrane was washed three times with TBST at intervals of 10 min and developed using an enhanced chemiluminescence kit (ECL; Amersham Pharmacia Biotech, Uppsala, Sweden). Then, membrane were photographed and for quantitative analysis, densitometric band values were determined using commercially available ChemiDoc™ XRS+ imaging system (Bio-Rad Laboratories, Hercules, CA, USA).

Statistical analyses

Data are expressed as means ± standard error of the mean (SEM). Statistical significance was determined using analysis of variance (ANOVA) followed by a multiple comparison test with Bonferroni adjustment. P values < 0.05 or < 0.01 were considered significant.

Results

SSEW reduced the number of inflammatory cells in BALF

To measure inflammatory cells, we counted the number of total cells, lymphocyte, neutrophils, macrophages, and eosinophils in BALF. The levels of inflammatory cells in BALF were significantly elevated in the OVA group compared with the NC group. However, SSEW treatment (100 and 200 mg/kg) markedly reduced the number of total cells, neutrophil and eosinophils than in the Mon group, which was a positive-control drug in this study (Figure 2).
Figure 2

Effect of SSEW on inflammatory cell accumulation in the BALF of OVA-induced mice. BALF was collected 48 h after the last OVA challenge, and the cells were isolated by cytospin and stained with Diff-Quick. NC, normal control group (vehicle); OVA, OVA-induced group (control); Mon, montelukast (30 mg/kg) + OVA-induced group (positive control); SSEW-100, SSEW (100 mg/kg) + OVA-induced group; SSEW-200, SSEW (200 mg/kg) + OVA-induced group. The values represent the mean ± S.E.M (n = 6/group). Significant differences at ##P < 0.01 compared with the NC group. Significant differences at *P < 0.05 and **P < 0.01 compared with the OVA-induced group.

SSEW decreased the Th1 cytokine and Th2 chemokine levels in BALF

To investigate the effects of SSEW on the T-cell immune response in asthmatic mice, we evaluated the production of Th1-type cytokines and the Th2-type chemokines in BALF. As shown in Figure 3A, the level of TNF-α was significantly decreased in the OVA group compared with the NC group. However, the Mon group exhibited a significantly increased level of TNF-α compared with the OVA group, and the level of TNF-α increased gradually in the SSEW groups (100 and 200 mg/kg) compared with the OVA group in a dose-dependent manner. In contrast, the level of eotaxin was significantly increased in the OVA group compared with the NC group. Finally, the administration of Mon and SSEW (100 and 200 mg/kg) significantly inhibited the level of eotaxin compared with what was observed in the OVA group (Figure 3B).
Figure 3

Effect of SSEW on Th1 cytokines and Th2 chemokine the in BALF of OVA-induced mice. Individual data were obtained using ELISA. (A) TNF-α and (B) eotaxin levels. NC, normal control group (vehicle); OVA, OVA-induced group (control); Mon, montelukast (30 mg/kg) + OVA-induced group (positive control); SSEW-100, SSEW (100 mg/kg) + OVA-induced group; SSEW-200, SSEW (200 mg/kg) + OVA-induced group. The values represent the mean ± S.E.M (n = 6/group). Significant differences at ##P < 0.01 compared with the NC group. Significant differences at *P < 0.05 and **P < 0.01 compared with the OVA-induced group.

SSEW decreased the levels of Th2 cytokines in BALF

To confirm the association between SSEW and Th2 responses in BALF from OVA-induced asthmatic mice, we assessed the levels of Th2-type cytokines in BALF. Figure 4 shows that the OVA group exhibited significantly elevated levels of Th2-type cytokines, including (A) IL-4, (B) IL-5, (C) IL-10, (D) IL-13, and (E) IL-33, compared with the NC group. However, the SSEW groups (100 and 200 mg/kg) showed significantly decreased levels of Th2 cytokines compared with the OVA group, similar to the Mon group (Figure 4A–E).
Figure 4

Effect of SSEW on Th2 cytokines in the BALF of OVA-induced mice. Individual data were obtained using ELISA.(A) IL-4, (B) IL-5, (C) IL-10, (D) IL-13, and (E) IL-33. NC, normal control group (vehicle); OVA, OVA-induced group (control); Mon, montelukast (30 mg/kg) + OVA-induced group (positive control); SSEW-100, SSEW (100 mg/kg) + OVA-induced group; SSEW-200, SSEW (200 mg/kg) + OVA-induced group. The values represent the mean ± S.E.M (n = 6/group). Significant differences at ##P < 0.01 compared with the NC group. Significant differences at *P < 0.05 and **P < 0.01 compared with the OVA-induced group.

SSEW improved histopathological changes in lung tissue

To analyze the effects of SSEW on the histological features of asthma, we performed H&E and PAS staining in lung tissues of OVA-induced asthmatic mice. OVA-induced lung tissues were characterized by peribronchial and perivascular inflammation caused by leukocyte infiltration compared with normal lung tissues; most infiltrating inflammatory cells were eosinophils. However, treatment with SSEW (100 and 200 mg/kg) markedly decreased eosinophil-rich leukocyte infiltration compared with the OVA group (Figure 5A,C). Mucus overproduction caused by goblet cell hyperplasia is characteristic of airway obstruction and airway remodeling. In the OVA group, mucus overproduction was clearly observed as a violet color in lung tissues compared with the NC group. However, administration of SSEW (100 and 200 mg/kg) markedly attenuated the mucus overproduction compared with the OVA group (Figure 5B,D).
Figure 5

Effect of SSEW on airway inflammation and airway goblet cell hyperplasia in the lung tissues of OVA-induced mice. Lung tissues were stained with (A) H&E solution and (B) PAS. The panel is magnified (200 ×). Representative photomicrographs of lung sections are shown. Yellow arrows indicated as airway inflammation and mucus production. (C) Inflammation and (D) mucus production index were determined using an image analyzer, respectively. NC, normal control group (vehicle); OVA, OVA-induced group (control); Mon, montelukast (30 mg/kg) + OVA-induced group (positive control); SSEW-100, SSEW (100 mg/kg) + OVA-induced group; SSEW-200, SSEW (200 mg/kg) + OVA-induced group. The values represent the mean ± S.E.M (n = 3/group). Significant differences at ##P < 0.01 compared with the NC group. Significant differences at **P < 0.01 compared with the OVA-induced group.

SSEW reduced the release of IgE levels in plasma and BALF

Because Th2-type cytokines promote airway inflammation in asthma via the increase in IgE levels, we evaluated the levels of IgE in plasma and BALF. As shown in Table 2, the levels of IgE were significantly increased in the OVA group (total IgE in BALF, 3.52 ± 0.36 ng/mL; total IgE and OVA-specific IgE in plasma, 1073.31 ± 123.77 and 54.57 ± 11.88; P < 0.01) compared with those observed in the NC group. However, SSEW treatment significantly inhibited the levels of total IgE (SSEW-100 and SSEW-200 in BALF, 2.73 ± 0.59 and 2.56 ± 0.37 ng/mL; SSEW-100 and SSEW-200 in plasma, 793.52 ± 83.49 and 771.48 ± 68.52 ng/mL) and OVA-specific IgE (SSEW-100 and SSEW-200 in plasma, 32.84 ± 15.23 and 45.35 ± 7.67 ng/mL) compared with the OVA group.
Table 2

Effect of SSEW on IgE levels in BALF and plasma

Groups

BALF

Plasma

Total IgE (ng/mL)

Total IgE (ng/mL)

OVA-specific IgE (ng/mL)

NC

1.95 ± 10.63

262.95 ± 107.60

< 0

OVA

3.52 ± 0.36##

1073.31 ± 123.77##

54.57 ± 11.88##

Mon

2.24 ± 0.50**

636.29 ± 102.28**

33.32 ± 10.35**

SSEW-100

2.73 ± 0.59*

793.52 ± 83.49**

32.84 ± 15.23*

SSEW-200

2.56 ± 0.37**

771.48 ± 68.52**

45.35 ± 7.67

NC, normal control group (vehicle); OVA, OVA-induced group (control); Mon, montelukast (30 mg/kg) + OVA-induced group (positive control); SSEW-100, SSEW (100 mg/kg) + OVA-induced group; SSEW-200, SSEW (200 mg/kg) + OVA-induced group. The values represent the mean ± S.E.M. (n = 6 in each group). Significant differences at ##P < 0.01 compared with the NC group. Significant differences at *P < 0.05 and **P < 0.01 compared with the OVA-induced group.

SSEW inhibited the expression of iNOS in lung tissue

To assess the association between the expression of the iNOS protein and bronchial asthma, we evaluated iNOS expression by western blotting. iNOS was markedly upregulated in the OVA group compared with the NC group. SSEW treatment (100 and 200 mg/kg) suppressed the upregulation of iNOS in a dose-dependent manner (Figure 6).
Figure 6

Effect of SSEW on iNOS expression in lung tissues of OVA-induced mice. Lung tissues were homogenized and iNOS protein expression was determined using western blot analysis. (A) Expression of iNOS in the lung tissue. (B) Relative ratio: The relative levels of iNOS expression (normalized to β-actin) were quantified. NC, normal control group (vehicle); OVA, OVA-induced group (control); Mon, montelukast (30 mg/kg) + OVA-induced group (positive control); SSEW-100, SSEW (100 mg/kg) + OVA-induced group; SSEW-200, SSEW (200 mg/kg) + OVA-induced group. The values represent the mean ± S.E.M (n = 3/group). Significant differences at ##P < 0.01 compared with the NC group. Significant differences at *P < 0.05 compared with the OVA-induced group.

Discussion

In the present study, we investigated the anti-inflammatory and anti-asthmatic effects of SSEW in an OVA-induced murine asthma model. OVA-induced mice showed an increased number of inflammatory cells, elevated IgE production, imbalance of Th1/Th2 cytokines and chemokines in BALF, mucus hypersecretion, eosinophil-rich leukocyte infiltration, and increased expression of iNOS in lung tissues. However, SSEW treatment increased the level of a Th1 cytokine (TNF-α) and decreased the levels of Th2 cytokines (IL-4, IL-5, IL-10, IL-13, and IL-33) and of a chemokine (eotaxin), IgE production, and the number of inflammatory cells (particularly, eosinophils and neutrophil) in BALF. The administration of SSEW also inhibited mucus overproduction, leukocyte infiltration, and expression of iNOS in lung tissues. First, we demonstrated that SSEW decreased the expression of iNOS in this model.

In traditional herbal medicine, herb mixtures are considered to produce a synergistic effect and a reduction of side effects via the interaction between the various herbs [16]. SSEW is a water extract that consists of Perillae Herba, Puerariae Radix, Pinelliae Tuber, Anthrisci Radix, Ginseng Radix, Poria Sclerotium, Aurantii Fructus, Platycodonis Radix, Glycyrrhizae Radix, Citri Unshius Pericarpium, Zingiberis Rhizoma, and Zizyphi Fructus (Table 1). Among these herbs, earlier studies reported that Perillae Herba, Pinelliae Tuber and Platycodonis Radix have antiasthmatic effects [17-19]; Puerariae Radix, Poria Sclerotium, and Aurantii Fructus have the anti-inflammatory effects [20-22]; Glycyrrhizae Radix, Zingiberis Rhizoma, and Zizyphi Fructus have antioxidant effects [23-25]; Anthrisci Radix and Citri Unshius Pericarpium have antiobesity effects [26,27]; and Ginseng Radix has an immunomodulating effect [28]. Accordingly, we predicted that SSEW, which is a mixture of these herbs, would have pharmacological effects, including antiasthmatic and anti-inflammatory effects, on OVA-induced airway inflammation in a murine asthma model.

The infiltration of eosinophils into the airways is a characteristic of asthma, and increased numbers of these cells have been found in BALF. The proinflammatory mediators derived from eosinophils are major contributors to the inflammation observed in asthma, which includes airway epithelial cell loss and damage, airway dysfunction, and mucus hypersecretion [29]. Our results demonstrated that the administration of SSEW significantly reduced the number of eosinophil-rich leukocytes and neutrophil in BALF. Histopathological examination of lung tissues paralleled the results of the analysis of the cell count in BALF. In support of these results, histopathological findings revealed that SSEW treatment markedly attenuated the number of infiltrated inflammatory cells and mucus hyperproduction of goblet cells in lung tissues. Eosinophils regulate the allergen-dependent Th2 immune responses mediated by dendritic cells and T lymphocytes and attenuate Th1 responses [30]. Hence, the imbalance of Th1/Th2 cell responses plays an important part in the development of asthma, and induces different immune responses and immunologically dysregulated states. Th1 cells produce proinflammatory cytokines; among them, TNF-α is a potent multifunctional cytokine and a chemoattractant for neutrophils and eosinophils [31]. In our experiments, SSEW treatment significantly increased the reduced levels of TNF-α by OVA induction. Th2 cells play an important role in the initiation and progression of allergic diseases, including asthma. Th2 cytokines (IL-4, IL-5, IL-10, IL-13, and IL-33) and chemokine (eotaxin) induce airway inflammatory responses, such as infiltration of inflammatory cells, eosinophil activation, IgE production, and mucus hypersecretion [32]. Our findings indicate that SSEW administration significantly decreased the increased Th2-type cytokines and chemokine production. Several studies have shown that modulation of Th1/Th2 cytokines can inhibit airway inflammation in OVA-induced mice [33,34]. Therefore, these findings suggest that SSEW attenuates airway inflammation through the modulation of the Th1/Th2 balance.

IgE, which is a key target for the development of anti-asthma strategies, is one of the most important factors in the progression of allergic reactions. Previous studies have indicated that anti-IgE treatment may be effective in allergic diseases [13,35]. In our study, SSEW treatment significantly reduced the increase in the levels of IgE (total IgE and OVA-specific IgE) that was related to the development of allergic reactions. These results suggest that SSEW is an effective agent in the treatment of allergic asthma.

Excessive NO contributes to the pathogenesis of airway inflammation, cellular injury, and tissue damage in the lung. iNOS caused by NO production is well known for its potential role in inducing airway diseases, including asthma. iNOS production is increased in asthmatic lung tissues and several types of inflammatory cells [36]. Previous studies have shown that iNOS expression is closely related to the recruitment of inflammatory cells in airways, including eosinophils and neutrophils [9]. In the present study, the expression of the iNOS protein was intensely increased in lung tissues of OVA-induced mice. In contrast, SSEW markedly decreased the overexpression of iNOS induced by OVA in a dose-dependent manner. These findings indicate that SSEW may attenuate the infiltration of inflammatory cells via the downregulation of iNOS expression. Taken together, our results suggest that SSEW exerts potent antiasthmatic and anti-inflammatory effects by suppressing proinflammatory cytokines and mediators related to eosinophils.

Conclusion

In summary, our results suggest that SSEW plays a pivotal role in OVA-induced airway inflammation by reducing the number of inflammatory cells (particularly, eosinophil and neutrophil), inflammatory cells infiltration, IgE levels, mucus production, and iNOS protein expression, and modulating Th1/Th2 cytokines. These findings suggest that SSEW has the potential to alleviate airway inflammation in the treatment of allergic asthma because of its antiasthma and anti-inflammatory properties.

Declarations

Acknowledgment

This study was supported by a grant from the Korea Institute of Oriental Medicine (K13030).

Authors’ Affiliations

(1)
Herbal Medicine Formulation Research Group, Korea Institute of Oriental Medicine
(2)
Natural Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology
(3)
Pharmacology, College of Veterinary Medicine, Chonnam National University

References

  1. Hamid Q, Tulic M. Immunobiology of asthma. Annu Rev Physiol. 2009;71:489–507.View ArticlePubMedGoogle Scholar
  2. Romagnani S. The role of lymphocytes in allergic disease. J Allergy Clin Immunol. 2000;105:399–408.View ArticlePubMedGoogle Scholar
  3. Mosmann TR, Moore KW. The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today. 1991;12:A49–53.View ArticlePubMedGoogle Scholar
  4. Woodfolk JA. Cytokines as a therapeutic target for allergic diseases: a complex picture. Curr Pharm Des. 2006;12:2349–63.View ArticlePubMedGoogle Scholar
  5. Spina D, Shah S, Harrison S. Modulation of sensory nerve function in the airways. Trends Pharmacol Sci. 1998;19:460–6.View ArticlePubMedGoogle Scholar
  6. Ricciardolo FL. Multiple roles of nitric oxide in the airways. Thorax. 2003;58:175–82.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Robbins RA, Barnes PJ, Springall DR, Warren JB, Kwon OJ, Buttery LD, et al. Expression of inducible nitric oxide in human lung epithelial cells. Biochem Biophys Res Commun. 1994;203:209–18.View ArticlePubMedGoogle Scholar
  8. Zhou DY, Du Q, Li RR, Huang M, Zhang Q, Wei GZ. Grape seed proanthocyanidin extract attenuates airway inflammation and hyperresponsiveness in a murine model of asthma by downregulating inducible nitric oxide synthase. Planta Med. 2011;77:1575–81.View ArticlePubMedGoogle Scholar
  9. Yoo D, Guk K, Kim H, Khang G, Wu D, Lee D. Antioxidant polymeric nanoparticles as novel therapeutics for airway inflammatory diseases. Int J Pharm. 2013;450:87–94.View ArticlePubMedGoogle Scholar
  10. Lu AP, Jia HW, Xiao C, Lu QP. Theory of traditional Chinese medicine and therapeutic method of diseases. World J Gastroenterol. 2004;10:1854–6.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Ryu NH, Park SM, Kang H, Shim BS, Kim SH, Chio SH, et al. Effect of Samsoeum on cytokine regulation of Mouse T cell. Korean J Orient Physiol Pathol. 2008;22:856–62.Google Scholar
  12. Lee SE, Shin JY, Lee SH. Anti-allergic effects of shensuyin. Korean J Orient Int Med. 2005;26:119–28.Google Scholar
  13. Lee MY, Lee JA, Seo CS, Ha H, Lee NH, Shin HK. Protective effects of Mentha haplocalyx ethanol extract (MH) in a mouse model of allergic asthma. Phytother Res. 2011;25:863–9.View ArticlePubMedGoogle Scholar
  14. Lynch KR, O’Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999;399:789–93.View ArticlePubMedGoogle Scholar
  15. Korenblat PE, Antileukotriene Working Group. The role of antileukotrienes in the treatment of asthma. Ann Allergy Asthma Immunol. 2001;86:31–9.View ArticlePubMedGoogle Scholar
  16. Bensky D, Barolet R. Chinese herbal medicine: formulas and strategies. Seattle: Eastland Press; 1990.Google Scholar
  17. Kang YS, Lee SC, Shin HD, Shin MK, Kim JH, Song HJ. Studies on the allergy asthma effect of Folium Perillae. Kor J Herbology. 2004;19:25–34.Google Scholar
  18. Jeong DH, Kim JH, Park SY, Choi JH. Effects of Pinelliae Rizoma (PR) on asthma induced intra-nasal instillation of ovalbumin in mice. J Korean Med Ophthalmol Otolaryngol Dermatol. 2008;21:38–54.Google Scholar
  19. Jung JK, Kang SY, Kim J, Lee SK, Park YK. Effects of Platycodi Radix ethanol extract on ovalbumin-induced allergic responses in mice. Kor J Herbology. 2012;27:123–9.View ArticleGoogle Scholar
  20. Kim SN, Kim HS, Nam GS, Hwang SW, Hwang SY. Inhibition of inflammatory-cytokines production and prostaglandin E2 activity by Puerariae Radix extracts. J Food Sci Nutr. 2006;35:28–34.Google Scholar
  21. Fuchs SM, Heinemann C, Schliemann-Willers S, Härtl H, Fluhr JW, Elsner P. Assessment of anti-inflammatory activity of Poria cocos in sodium lauryl sulphate-induced irritant contact dermatitis. Skin Res Technol. 2006;12:223–7.View ArticlePubMedGoogle Scholar
  22. Kim SJ, Park SK. Antioxidative and anti-inflammatory effects of Aurantii Fructus Immaturus pharmacopuncture. Korean J Acupunct. 2010;27:13–24.Google Scholar
  23. Yoon MY, Jun KI, Son ES, Kim JH, Kim Y, Park E, et al. Induction of glutathione S-transferase activity by the extracts of Glycyrrhiza uralensis Fischer. J Korean Soc Appl Biol Chem. 2008;51:228–32.View ArticleGoogle Scholar
  24. Jeong GS, Li B, Lee DS, Choi HG, Kim YC. Neuroprotective Effects of the extract of Zingiberis Rhizoma. Kor J Pharmacogn. 2010;41:190–5.Google Scholar
  25. Jeong HM, Kim YS, Ahn SJ, Auh MS, Ahn JB, Kim KY. Effects of Zizyphus jujuba var. boeunesis extracts on the growth of intestinal microflora and its antioxidant activities. J Korean Soc Food Nutr. 2011;40:500–8.View ArticleGoogle Scholar
  26. Shin JK, Cha GY, Kim HJ, Hwang JH, Han KH, Seo HJ, et al. Exmination of anti-obesity effect of regional special natural products of Anthrisci radix, Psoraleae semen, Siegesbeckiae herba and Corni fructus. KSBB J. 2009;24:549–55.Google Scholar
  27. Park CH, Jung HK, Jeong YK, Hong JH, Lee GD, Park CD. Effects of Citrus Peel ethanol extract on serum lipid and body fat of high-fat-diet-fed rats. Korean J Food Preserv. 2011;18:567–74.View ArticleGoogle Scholar
  28. Liou CJ, Huang WC, Tseng J. Long-term oral administration of ginseng extract modulates humoral immune response and spleen cell functions. Am J Chin Med. 2005;33:651–61.View ArticlePubMedGoogle Scholar
  29. Kay AB. The role of eosinophils in the pathogenesis of asthma. Trends Mol Med. 2005;11:148–52.View ArticlePubMedGoogle Scholar
  30. Jacobsen EA, Zellner KR, Colbert D, Lee NA, Lee JJ. Eosinophils regulate dendritic cells and Th2 pulmonary immune responses following allergen provocation. J Immunol. 2011;187:6059–68.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Lukacs NW, Strieter RM, Chensue SW, Widmer M, Kunkel SL. TNF-alpha mediates recruitment of neutrophils and eosinophils during airway inflammation. J Immunol. 1995;154:5411–7.PubMedGoogle Scholar
  32. Corrigan CJ, Kay AB. T cells and eosinophils in the pathogenesis of asthma. Immunol Today. 1992;13:501–7.View ArticlePubMedGoogle Scholar
  33. Lee MY, Shin IS, Lim HS, Shin HK. A water extract of Samchulkunbi-tang attenuates airway inflammation by inhibiting iNOS and MMP-9 activities in an ovalbumin-induced murine asthma model. BMC Complement Altern Med. 2012;12:257.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Ma C, Ma Z, Liao XL, Liu J, Fu Q, Ma S. Immunoregulatory effects of Glycyrrhizic acid exerts anti-asthmatic effects via modulation of Th1/Th2 cytokines and enhancement of CD4 + CD25 + Foxp3+ regulatory T cells in ovalbumin-sensitized mice. J Ethnopharmacol. 2013;148:755–62.View ArticlePubMedGoogle Scholar
  35. Hamelmann E, Tadeda K, Oshiba A, Gelfand EW. Role of IgE in the development of allergic airway inflammation and airway hyperresponsiveness–a murine model. Allergy. 1999;54:297–305.View ArticlePubMedGoogle Scholar
  36. Islam T, Breton C, Salam MT, McConnell R, Wenten M, Gauderman WJ, et al. Role of inducible nitric oxide synthase in asthma risk and lung function growth during adolescence. Thorax. 2010;65:139–45.View ArticlePubMedGoogle Scholar

Copyright

© Jeon et al.; licensee BioMed Central. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement